Literature DB >> 8417115

Functional consequences of engagement of the T cell receptor by low affinity ligands.

J Alexander1, K Snoke, J Ruppert, J Sidney, M Wall, S Southwood, C Oseroff, T Arrhenius, F C Gaeta, S M Colón.   

Abstract

The mechanisms involved in TCR antagonism by Ag analog/MHC have been analyzed. A detailed structure-activity relationship study indicated that modification of any of the major T cell contact residues of the peptide molecule can yield a powerful antagonist. It was also shown that as the analog structure increased in similarity to the Ag, the capacity to antagonize Ag-TCR interaction increased up to the point that the analogs themselves became antigenic. These data strongly suggest an affinity-related mechanism whereby a certain affinity is required for signaling through the TCR, and that below this level there can be sufficient affinity to engage the receptor such that triggering does not occur and antagonism can be detected. Taking advantage of this information, antagonist peptides active down to the 10 nM range were engineered. Thus, this approach demonstrates for the first time a rational approach to designing effective, selective low m.w. compounds with high potential in treatment of allergies and autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8417115

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  Structure of a covalently stabilized complex of a human alphabeta T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1.

Authors:  J Hennecke; A Carfi; D C Wiley
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

2.  Fine specificity and cross-clade reactivity of HIV type 1 Gag-specific CD4+ T cells.

Authors:  Philip J Norris; Howell F Moffett; Christian Brander; Todd M Allen; Kristin M O'Sullivan; Lisa A Cosimi; Daniel E Kaufmann; Bruce D Walker; Eric S Rosenberg
Journal:  AIDS Res Hum Retroviruses       Date:  2004-03       Impact factor: 2.205

Review 3.  Strategies to use immune modulators in therapeutic vaccines against cancer.

Authors:  Jay A Berzofsky; Masaki Terabe; Lauren V Wood
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

Review 4.  Modulation of the immune response with T-cell epitopes: the ultimate goal for specific immunotherapy of autoimmune disease.

Authors:  P J Fairchild; C J Thorpe; P J Travers; D C Wraith
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

5.  Cloning, characterization, and expression of a cDNA encoding an inducible nitric oxide synthase from the human chondrocyte.

Authors:  I G Charles; R M Palmer; M S Hickery; M T Bayliss; A P Chubb; V S Hall; D W Moss; S Moncada
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

6.  Kinetic discrimination in T-cell activation.

Authors:  J D Rabinowitz; C Beeson; D S Lyons; M M Davis; H M McConnell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

7.  Development of a strategy and computational application to select candidate protein analogues with reduced HLA binding and immunogenicity.

Authors:  Sandeep Kumar Dhanda; Alba Grifoni; John Pham; Kerrie Vaughan; John Sidney; Bjoern Peters; Alessandro Sette
Journal:  Immunology       Date:  2017-09-28       Impact factor: 7.397

8.  Antagonism of HIV-specific CD4+ T cells by C-terminal truncation of a minimum epitope.

Authors:  Philip J Norris; Jennifer D Stone; Nadezhda Anikeeva; John W Heitman; Ingrid C Wilson; Dale F Hirschkorn; Margaret J Clark; Howell F Moffett; Thomas O Cameron; Yuri Sykulev; Lawrence J Stern; Bruce D Walker
Journal:  Mol Immunol       Date:  2005-10-07       Impact factor: 4.407

9.  Effects of in vivo administration of anti-IL-10 monoclonal antibody on the host defence mechanism against murine Salmonella infection.

Authors:  T Arai; K Hiromatsu; H Nishimura; Y Kimura; N Kobayashi; H Ishida; Y Nimura; Y Yoshikai
Journal:  Immunology       Date:  1995-07       Impact factor: 7.397

10.  Induction of dominant transplantation tolerance by an altered peptide ligand of the male antigen Dby.

Authors:  Tse-Ching Chen; Herman Waldmann; Paul J Fairchild
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.